Specific aims of the study include:
1. To obtain serum samples from patients with newly diagnosed pancreatic cancer at baseline before treatment and monthly throughout treatment.
2. To analyze the miRNA profiles present at each time point.
3. To determine miRNAs that may distinguish pancreatic patients from unaffected individuals. This could be developed into a diagnostic test.
4. To determine miRNAs whose levels correlate with treatment response, both in patients with and without elevations in the serum tumor marker CA 19-9.
Age
18–any
Sex
ALL
Healthy volunteers
Accepted
You may be eligible if
Have biopsy proven adenocarcinoma of the pancreas
Have initially inoperable disease, classified as either locally advanced or metastatic disease
* Recurrent disease after a Whipple procedure is allowed
* Patients who are able to undergo resection after neoadjuvant therapy will continue to be followed after resection
Have radiographically measurable disease
Have an ECOG performance status of 2 or less
Be willing to contribute the required information and specimens
Provide written signed consent to participate
You may not be if
Having received prior anti-cancer treatments for metastatic pancreatic cancer
Concurrently receiving systemic therapy for another cancer except androgen deprivation therapy for stable/controlled prostate cancer
Presence of other active cancer except for: adequately treated local basal or squamous cell carcinoma of the skin, cervical carcinoma in situ, superficial bladder cancer, asymptomatic prostate cancer without known metastatic disease and with no requirement for therapy or requiring only hormonal therapy and with normal prostate-specific antigen for \>1 year prior to start of trial. Other adequately treated Stage 1 or 2 cancer currently in complete remission, or any other cancer that has been in complete remission for \> 5 years is allowable
Clareo Health | The Role of MicroRNA in the Diagnosis, Prognosis and Response to Treatment in Pancreatic Cancer
